^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    LN-145-S1

    i
    Other names: LN-145-S1, autologous tumor infiltrating lymphocytes, TIL
    Associations

    News

    Trials
    Company:
    Iovance Biotherap
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    7ms
    NCI-2018-00918: LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Jun 2024 --> Jun 2025 | Trial completion date: Jun 2024 --> Jun 2025
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • CD8 (cluster of differentiation 8) • CD28 (CD28 Molecule) • CD27 (CD27 Molecule)
    |
    CD8 expression • CD28 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • LN-145 • LN-145-S1
    9ms
    IOV-COM-202: Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors (clinicaltrials.gov)
    P2, N=178, Recruiting, Iovance Biotherapeutics, Inc. | Trial completion date: Dec 2024 --> Aug 2029 | Trial primary completion date: Dec 2023 --> Aug 2029
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • Amtagvi (lifileucel) • LN-145 • LN-145-S1
    1year
    Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck (clinicaltrials.gov)
    P2, N=64, Completed, Iovance Biotherapeutics, Inc. | N=112 --> 64
    Enrollment change • Metastases
    |
    LN-145 • LN-145-S1
    over1year
    NCI-2018-00918: LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=95 --> 30
    Enrollment closed • Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • LN-145 • LN-145-S1
    over1year
    NCI-2018-00918: LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas (clinicaltrials.gov)
    P2, N=95, Recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Jun 2023 --> Jun 2024
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • LN-145 • LN-145-S1
    almost4years
    IOV-COM-202: Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors (clinicaltrials.gov)
    P2, N=135, Recruiting, Iovance Biotherapeutics, Inc. | N=75 --> 135
    Clinical • Enrollment change • PD(L)-1 Biomarker
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK mutation
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • Amtagvi (lifileucel) • LN-145 • LN-145-S1